Related Experiment Video
Updated: Sep 11, 2025
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
Published on: February 2, 2024
IL-7 armed binary CAR T cell strategy to augment potency against solid tumors
Alejandro G Torres Chavez1, Mary K McKenna1, Anmol Gupta1
1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, United States.
Introduction:
Clinical studies of T cells engineered with chimeric antigen receptor (CAR) targeting CD19 in B-cell malignancies have demonstrated that relapse due to target antigen (CD19) loss or limited CAR T cell persistence is a common occurrence. The possibility of such events is greater in solid tumors, which typically display more heterogeneous antigen expression patterns and are known to directly suppress effector cell proliferation and persistence. T cell engineering strategies to overcome these barriers are being explored. However, strategies to simultaneously address both antigen heterogeneity and T cell longevity, while localizing anti-tumor effects at disease sites, remain limited.
Methods:
In this study we explore a dual antigen targeting strategy by directing independent CARs against the solid tumor targets PSCA and MUC1. To enhance functional persistence in a tumor-localized manner, we expressed the transgenic IL-7 cytokine and receptor (IL-7Rα) in respective CAR products.
Results:
This binary strategy, which incorporates dual antigen targeting with transgenic cytokine support, resulted in enhanced potency, T cell expansion, and durable antitumor effects in a pancreatic tumor model compared to single antigen targeting or dual antigen targeting in absence of the transgenic cytokine support.
Discussion:
The transgenic IL-7 armed binary CAR T cell approach could improve the efficacy of CAR-based therapies for solid tumors.
Insights
This study introduces a dual-targeting chimeric antigen receptor (CAR) T cell therapy for solid tumors, enhanced with IL-7 cytokine support. This approach improves T cell persistence and anti-tumor effects, offering a promising strategy for difficult-to-treat cancers.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T cell therapy shows promise for B-cell malignancies but faces challenges in solid tumors, including antigen loss, heterogeneity, and poor T cell persistence.
- Current strategies often struggle to simultaneously address antigen diversity and T cell longevity within the tumor microenvironment.
Purpose of the Study:
- To develop and evaluate a novel CAR T cell strategy for solid tumors that overcomes antigen heterogeneity and enhances T cell persistence.
- To investigate the efficacy of a dual-targeting CAR T cell system engineered with transgenic IL-7 cytokine support.
Main Methods:
- Engineered T cells to express independent CARs targeting two distinct solid tumor antigens: PSCA and MUC1.
- Incorporated transgenic Interleukin-7 (IL-7) cytokine and receptor (IL-7Rα) expression within the CAR T cells to promote localized persistence and function.
Main Results:
- The dual-targeting CAR T cell strategy with IL-7 support demonstrated superior anti-tumor potency and durable effects in a pancreatic tumor model.
- Compared to single-target CARs or dual-target CARs without IL-7, this enhanced binary approach led to significant T cell expansion and sustained anti-tumor activity.
- The combination of dual antigen recognition and cytokine support effectively addressed tumor heterogeneity and improved T cell longevity.
Conclusions:
- Transgenic IL-7 armed binary CAR T cells represent a potent therapeutic strategy for solid tumors.
- This approach holds potential for improving the efficacy of CAR T cell therapies in challenging solid tumor indications.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
06:10Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
